Energetic characteristics of cisplatin resistant ovarian carcinoma cells

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 443-448

  Dorward, Ann M ^b   Singh, Gurmit ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b NONE

Author keywords

Cisplatin; Glycolysis; Mitochondria; Resistance; Respiration

Indexed keywords

CISPLATIN; OLIGOMYCIN;

ARTICLE; CELL MEMBRANE POTENTIAL; CELL METABOLISM; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; OVARY CARCINOMA; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL;

CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; FEMALE; GLYCOLYSIS; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MITOCHONDRIA; OVARIAN NEOPLASMS;

EID: 0029871478     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Perez RP, Hamilton TC and Ozols RF: Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol and Therapeutics 48: 19-27, 1990.
2. Andrews PA and Albright KD: Mitochondrial Defects in cis-Diamminedichloroplatinum(II)-resistant Human Ovarian Carcinoma Cells. Cancer Res 52: 1895-1901, 1992.
3. Zinkewich-Peotti K and Andrews PA: Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 52: 1902-1906, 1992.
4. Balaban RS: Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol 258: C377-C389, 1990.
5. Rago R, Mitchen J and Wilding G: DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem 191: 31-34, 1990.
6. Maftah A, Petit JM, Ratinaud M, and Julien R: 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem Biophys Res Comm 164: 185-190, 1989.
7. Petit JM, Maftah A, Ratinaud M, and Julien R: 10N-nonyl acridine orange interacts with cardiolipin and allows the quantification of this phospholipid in isolated mitochondria Eur J Biochem 209: 267-273, 1992.
8. Bustamante E, Morris HP and Pedersen PL: Energy metabolism of tumor cells. JBC 256: 8699-8704, 1981.
9. Andrews PA, Murphy MP and Howell SB: Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Mol Pharmacol 30: 643-650, 1986.
10. Andrews PA, Schiefer MA, Murphy MP and Howell SB: Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem-Biol Interact 65: 51-58, 1988.
11. Andrews PA, Velury S, Mann SC and Howell SB: cis-Diammmedichloroplatinum(Il) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48: 68-73, 1988.
12. Mann SC, Andrews PA and Howell SB: Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25: 236-240, 1990.
13. Moorehead RA, Armstrong SG, Rainbow AJ and Singh G: Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). (submitted for publication), 1995.
14. 31P NMR spectroscopy. Biochem Biophys Res Comm 183: 114-120, 1992.
15. Singh G: A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicol 58: 71-80, 1989.
16. Rosen M, Figliomeni M and Simpkins H: The interaction of platinum antitumor drugs with mouse liver mitochondria. Intl J Exptl Pathol 73: 61-74, 1992.
17. Zhang J and Lindup WE: Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45: 2215-2222, 1993.
18. Gordon JA and Gattone VHI: Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250: F991-F998, 1994.
19. Reed DJ: Glutathione: Toxicological implications. Ann Rev Pharm Toxicol 30: 603-631, 1990.
20. Gunter TE, Gunter KK, Sheu S and Gavin CE: Mitochondrial calcium transport: physiological and pathological relevance. Am J Physiol 267: C313-C339, 1994.
21. Buttke TM and Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10, 1994.
22. Uslu R and Bonavida B: Free radicals dependent and independent pathways of CDDP-mediated cytotoxicity and apoptosis in ovarian tumor cell lines. Intl J Oncol 6, 1003-1009, 1995.
23. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metast Rev 11: 121-139, 1992.
24. Kerr JFR, Winterford CM and Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
25. Barry MA, Behnke CA and Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40, 2353-2362, 1990.
26. Sorenson CM, Barry MA and Eastman A: Analysis of events associated with cell cycle Arrest at G2 phase and cell death induced by cisplatin. JNCI 82: 749-755, 1990.
27. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
28. Evans DL and Dive C. Effect of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 53: 2133-2139, 1993.
29. Ormerod MG, O'Neill CF, Robertson D and Harrap KR: Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exptl Cell Res 211: 231-237, 1994.